Related Experiment Videos
Treating apathy in Alzheimer's disease
Patricia A Boyle1, Paul F Malloy
1Department of Neurology, Boston University School of Medicine, Boston, MA 02116, USA.
Dementia and Geriatric Cognitive Disorders
|October 18, 2003
Summary
Apathy affects over 70% of Alzheimer's disease (AD) patients, causing motivation loss. Acetylcholinesterase inhibitors show promise in reducing apathy in AD, alongside other treatments.
Area of Science:
- Neuroscience
- Neurology
- Gerontology
Background:
- Apathy, characterized by reduced initiation and motivation, is the most common neuropsychiatric symptom in Alzheimer's disease (AD), affecting over 70% of patients.
- This syndrome is linked to functional decline in patients and increased caregiver stress.
- AD-related apathy is associated with frontal system dysfunction, potentially involving cholinergic deficits and frontal neuropathology.
Purpose of the Study:
- To review the assessment and treatment strategies for apathy in Alzheimer's disease (AD).
- To emphasize the efficacy of acetylcholinesterase inhibitors in managing apathy in AD.
- To discuss other potential pharmacologic agents and combined interventions, and to suggest future research directions.
Main Methods:
- Literature review focusing on the assessment and treatment of apathy in Alzheimer's disease.
- Emphasis on studies evaluating acetylcholinesterase inhibitors for apathy reduction.
- Discussion of alternative pharmacologic and behavioral interventions.
Main Results:
- Apathy is a prevalent and debilitating symptom in Alzheimer's disease (AD).
- Acetylcholinesterase inhibitors demonstrate utility in alleviating apathy in AD patients.
- Further research is needed for combined pharmacologic-behavioral approaches.
Conclusions:
- Apathy is a significant challenge in Alzheimer's disease (AD) management.
- Acetylcholinesterase inhibitors represent a key therapeutic option for AD-related apathy.
- Integrated treatment strategies and continued research are essential for improving patient outcomes.